Recommendations and rationale for the treatment of pelvic inflammatory disease

References

• Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. MMWR55(No RR-11), 56–61 (2006).
   Google Scholar
• Rein DB, Kassler WJ, Irwin KL, Rabiee L. Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing, but still substantial. Obstet. Gynecol.95, 397–402 (2000).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance. CDC, GA, USA (2008).
   Google Scholar
• Patton DL, Moore DE, Spadoni LR, Soules MR, Halbert SA, Wang SP. A comparison of the fallopian tube’s response to overt and silent salpingitis. Obstet. Gynecol.73, 622–630 (1989).
   PubMed Web of Science ®Google Scholar
• Eschenbach DA, Buchanan TM, Pollack HM et al. Polymicrobial etiology of acute pelvic inflammatory disease. N. Engl. J. Med.293, 166–171 (1975).
   PubMed Web of Science ®Google Scholar
• Mardh PA, Ripa T, Svensson L, Westrom L. Chlamydia trachomatis infection in patients with acute salpingitis. N. Engl. J. Med.296(24), 1377–1379 (1977).
   PubMed Web of Science ®Google Scholar
• Sweet RL, Draper DL, Schachter J, James J, Hadley WK, Brooks GF. Microbiology and pathogenesis of acute salpingitis as determined by laparoscopy: what is the appropriate site to sample? Am. J. Obstet. Gynecol.138, 985–989 (1980).
   PubMed Web of Science ®Google Scholar
• Cohen CR, Mugo NR, Astete SG, et al. Detection of Mycoplasma genitalium in women with laparoscopically diagnosed acute salpingitis. Sex. Transm. Infect.81, 463–466 (2005).
   PubMed Web of Science ®Google Scholar
• Wiesenfeld HC, Hillier SL, Krohn MA, et al. Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet. Gynecol.100, 456–463 (2002).
   PubMed Web of Science ®Google Scholar
• Eckert LO, Thwin SS, Hillier SL, Kiviat NB, Eschenbach DA. The antimicrobial treatment of subacute endometritis: a proof of concept study. Am. J. Obstet. Gynecol.190, 305–313 (2004).
   PubMed Web of Science ®Google Scholar
• Haggerty CL, Totten PA, Astete SG, Ness RB. Mycoplasma genitalium among women with nongonococcal, nonchlamydial pelvic inflammatory disease. Infect. Dis. Obstet. Gynecol.30, 184 (2006).
   Google Scholar
• Ness RB, Kip K E, Hillier SL et al. A cluster analysis of bacterial vaginosis- associated microflora and pelvic inflammatory disease Am. J. Epidemiol.162, 585–590 (2005).
   PubMed Web of Science ®Google Scholar
• Short VL, Totten PA, Ness RB, Astet SG, Kelsey SF, Haggerty CL. Clinical presentation of Mycoplasma genitalium infection versus Neisseria gonorrhoeoe infection among women with pelvic inflammatory disease. Clin. Infect. Dis.48, 41–47 (2009).
   PubMed Web of Science ®Google Scholar
• Haggerty CL, Totten PA, Astete SG et al. Failure of cefoxitin and doxycycline to eradicate endometrial Mycoplasma genitalium and the consequence for clinical cure of pelvic inflammatory disease. Sex. Transm. Infect.84, 338–342 (2008).
   PubMed Web of Science ®Google Scholar
• Ness RB, Soper DE, Holley RL et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am. J. Obstet. Gynecol.186, 929–937 (2002).
   PubMed Web of Science ®Google Scholar
• Landers DV, Sweet RL. Current trends in the diagnosis and treatment of tuboovarian abscess. Am. J. Obstet. Gynecol.151, 1098–1110 (1985).
   PubMed Web of Science ®Google Scholar
• Reed SD, Landers DV, Sweet RL. Antibiotic treatment of tuboovarian abscess: comparison of broad-spectrum β-lactam agents versus clindamycin-containing regimens. Am. J. Obstet. Gynecol.164, 1556–1562 (1991).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Updated Treatment Recommendations for Gonococcal Infections and Associated Conditions. CDC, GA, USA (2007).
   Google Scholar
• Soper DE, Brockwell NJ, Dalton HP, Johnson D. Microbial etiology of urban emergency department acute salpingitis: treatment with ofloxacin. Am. J. Obstet. Gynecol.167, 653–660 (1992).
   PubMed Web of Science ®Google Scholar
• Crombleholme WR, Schachter J, Ohm-Smith M, Luft J, Whidden R, Sweet RL. Efficacy of single-agent therapy for the treatment of acute pelvic inflammatory disease with ciprofloxacin. J. Med.87, 142S–147S (1989).
   Google Scholar
• Martens MG, Gordon S, Yarborough DR, Faro S, Binder D, Berkeley A. Multicenter randomized trial of ofloxacin versus cefoxitin and doxycycline in outpatient treatment of pelvic inflammatory disease. Ambulatory PID Research Group. South Med. J.86, 604–610 (1993).
   PubMed Web of Science ®Google Scholar
• Ross JD, Cronje HS, Paszkowski T et al. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomized trial. Sex. Transm. Infect.82, 446–451 (2006).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Update to CDC’s sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for the treatment of gonococcal infections. MMWR Recomm. Rep.56(RR-14), 332–336 (2007).
   Google Scholar
• Eschenbach D. Treatment of pelvic inflammatory disease. Clin. Infect. Dis.44, 961–963 (2007).
   PubMed Web of Science ®Google Scholar
• Judlin P, Liao Q, Liu Z et al. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG117(12), 1475–1484 (2010).
   PubMed Web of Science ®Google Scholar
• Heystek M, Ross JDC. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. Int. J. STD AIDS20, 690–695 (2009).
   PubMed Web of Science ®Google Scholar
• Stass H, Kubitza D, Aydeniz B et al. Penetration and accumulation of moxifloxacin in uterine tissue. Int. J. Gynecol. Obstet.102, 132–136 (2008).
   PubMed Web of Science ®Google Scholar
• Bradshaw CS, Chen MY, Fairley CK. Persistence of Mycoplasma genitalium following azithromycin therapy. PLoS ONE3(11), e3618 (2008).
   Google Scholar
• Bradshaw CS, Jensen JS, Tabrizi SN et al. Azithromycin failure. Emerging Infect. Dis.12(7), 1149–1152 (2006).
   PubMed Web of Science ®Google Scholar
• Haggerty CL, Ness RB. Epidemiology, pathogenesis and treatment of pelvic inflammatory disease. Expert Rev. Anti Infect. Ther.4, 235–247 (2006).
   PubMedGoogle Scholar
• Piyadigamage A, Wilson J. Improvement in the clinical cure rate of outpatient management of pelvic inflammatory disease following a change in therapy. Sex. Transm. Infect.81, 233–235 (2005).
   PubMed Web of Science ®Google Scholar
• Goldstein EJ, Nesbit CA, Citron DM. Comparative in vitro activities of azithromycin, Bay y 3118, levofloxacin, sparfloxacin, and 11 other oral antimicrobial agents against 194 aerobic and anaerobic bite wound isolates. Antimicrob. Agents. Chemother.39, 1097–1100 (1995).
   PubMed Web of Science ®Google Scholar
• Taylor-Robinson D, Bebear C. Antibiotic susceptibilities of mycoplasmas and treatment of mycoplasmal infections. J. Antimicrob. Chemother.40, 622–630 (1997).
   PubMed Web of Science ®Google Scholar
• Taylor-Robinson D. Mycoplasma genitalium – an up-date. Int. J. STD AIDS13, 145–151 (2002).
   PubMed Web of Science ®Google Scholar
• Rustomjee R, Kharsany AB, Connolly C A, Karim SS. A randomized controlled trial of azithromycin versus doxycycline/ciprofloxacin for the syndromic management of sexually transmitted infections in a resource – poor setting. J. Antimicrob. Chemother.49, 875–878 (2002).
   PubMed Web of Science ®Google Scholar
• Bevan CD, Ridgway GL, Rothermel CD. Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. J. Int. Med. Res.31, 45–54 (2003).
   PubMed Web of Science ®Google Scholar
• Malhotra M, Sharma JB, Batra S, Arora R, Sharma S. Ciprofloxacin–tinidazole combination, fluconazole–azithromycin–secnidazole–kit and doxycycline–metronidazole combination therapy in syndromic management of pelvic inflammatory disease: a prospective randomized controlled trial. Indian J. Med. Sci.57, 549–555 (2003).
   PubMedGoogle Scholar
• Patton DL, Sweeney YT, Stamm WE. Significant reduction in inflammatory response in the macaque model of Chlamydia pelvic inflammatory disease with azithromycin treatment. J. Infect. Dis.192, 129–135 (2005).
   PubMed Web of Science ®Google Scholar
• Savaris RF, Teixeira LM, Torres TG, Edelweiss MIA, Moncada J, Schachter J. Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease. A randomized controlled trial. Obstet. Gynecol.110, 53–60 (2007).
   PubMed Web of Science ®Google Scholar
• Mena LA, Mroczkowski TF, Nsuami M et al. A randomized comparison of azithromycin and doxycycline for the treatment of mycoplasma genitalium-positive urethritis in men. Clin. Infect. Dis.48, 1649–1654 (2009).
   PubMed Web of Science ®Google Scholar
• Gilbert DN, Leggett JE. Aminoglycosides. In: Principles and Practice of Infectious Diseases. 7th Edition. Churchill Livingstone Elsevier, PA, USA, 367 (2010).
   Google Scholar
• McNeeley SG, Hendrix SL, Mazzoni MM, Kmak DC, Ransom SB. Medically sound, cost-effective treatment for pelvic inflammatory disease and tuboovarian abscess. Am. J. Obstet. Gynecol.178, 1272–1278 (1998).
   PubMed Web of Science ®Google Scholar
• Sivapalasingam S, Steigbigel NH. Macrolides, clindamcyin, and ketolides. In: Principles and Practice of Infectious Diseases. 7th Edition. Churchill Livingstone Elsevier, PA, USA, 442 (2010).
   Google Scholar
• Beigi RH, Austin MN, Meyn LA, Krohn MA, Hillier SL. Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am. J. Obstet. Gynecol.191, 1124–1129 (2004).
   PubMed Web of Science ®Google Scholar
• Sweet RL. Treatment strategies for pelvic inflammatory disease. Expert. Opin. Pharacother.10, 823–837 (2009).
   PubMed Web of Science ®Google Scholar
• Walker CK, Wiesenfeld HC. Antibiotic therapy for acute pelvic inflammatory disease: the 2006 centers for disease control and prevention sexually transmitted diseases treatment guidelines. Clin. Infect. Dis.44, S111–S122 (2007).
   PubMed Web of Science ®Google Scholar
• Wiesenfeld HC, Sweet RL. Progress in the management of tuboovarian abscesses. Clin. Obstet. Gynecol.36, 433–434 (1993).
   PubMed Web of Science ®Google Scholar
• Rivlin ME, Hunt JA. Ruptured tubo–ovarian abscess: is hysterectomy necessary? Obstet. Gynecol.50, 518–522 (1977).
   PubMed Web of Science ®Google Scholar
• Ross J, Judlin P, Nilas L. European guideline for the management of pelvic inflammatory disease. Int. J. STD AIDS18, 662–666 (2008).
   Web of Science ®Google Scholar
• Wiesenfeld HC, Sweet RL, Ness RB, Krohn MA, Amotegui AJ, Hillier SL. Comparison of acute and subclinical pelvic inflammatory disease. Sex. Transm. Dis.32, 400–405 (2005).
   PubMed Web of Science ®Google Scholar
• Jacobson L, Westrom L. Objectivized diagnosis of acute pelvic inflammatory disease. Diagnostic and prognostice value of routine laparoscopy. Am. J. Obstet. Gynecol.105, 1088–1098 (1969).
   PubMed Web of Science ®Google Scholar
• Workowski KA, Berman SM, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. MMWR Recomm. Rep.55(RR-11), 1–94 (2006). Erratum in: MMWR Recomm. Rep.55, 7 (2006).
   PubMedGoogle Scholar